Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 May 7;21(17):5359-71.
doi: 10.3748/wjg.v21.i17.5359.

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Noortje G Rossen  1 , John K MacDonald  1 , Elisabeth M de Vries  1 , Geert R D'Haens  1 , Willem M de Vos  1 , Erwin G Zoetendal  1 , Cyriel Y Ponsioen  1
Affiliations
Meta-Analysis

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Noortje G Rossen et al. World J Gastroenterol. .

Abstract

Aim: To study the clinical efficacy and safety of Fecal microbiota transplantation (FMT). We systematically reviewed FMT used as clinical therapy.

Methods: We searched MEDLINE, EMBASE, the Cochrane Library and Conference proceedings from inception to July, 2013. Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category, on an intention-to-treat basis.

Results: We included 45 studies; 34 on Clostridium difficile-infection (CDI), 7 on inflammatory bowel disease, 1 on metabolic syndrome, 1 on constipation, 1 on pouchitis and 1 on irritable bowel syndrome (IBS). In CDI 90% resolution of diarrhea in 33 case series (n = 867) was reported, and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial (RCT) (n = 16). In ulcerative colitis (UC) remission rates of 0% to 68% were found (n = 106). In Crohn's disease (CD) (n = 6), no benefit was observed. In IBS, 70% improvement of symptoms was found (n = 13). 100% Reversal of symptoms was observed in constipation (n = 3). In pouchitis, none of the patients (n = 8) achieved remission. One RCT showed significant improvement of insulin sensitivity in metabolic syndrome (n = 10). Serious adverse events were rare.

Conclusion: FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome.

Keywords: Clostridium difficile infection; Fecal microbiota transplantation; Inflammatory bowel disease; Metabolic syndrome; Microbiota.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Identification, screening, eligibility and inclusion of studies. IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.
See this image and copyright information in PMC

References

    1. Ge H. Zhou Hou Bei Ji Fang. Tianjin: Tianjin Science and Technology; 2000.
    1. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–859. - PubMed
    1. Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211–215. - PubMed
    1. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164. - PubMed
    1. Borody T, Wettstein A, Campbell J, Leis S, Torres M, Finlayson S, Nowak A. Fecal microbiota transplantation in ulcerative colitis: Review of 24 years experience. Am J Gastroenterol Conf 77th Annu Sci Meet Am Coll Gastroenterol. 2012;107:S665.

Publication types